A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Trial Profile

A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Telomelysin (Primary)
  • Indications Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Oncolys BioPharma
  • Most Recent Events

    • 07 Jul 2017 According to an Oncolys BioPharma media release, this trial will enroll patients in two sites, Okayama University Hospital and National Cancer Centre Hospital East in Chiba Prefecture.
    • 07 Jul 2017 Status changed from not yet recruiting to recruiting, according to an Oncolys BioPharma media release.
    • 07 Jul 2017 According to an Oncolys BioPharma media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top